Identification of hepatic off-targets of anti-HIV protease inhibitors involved in organelle stress response and liver injury

Cheng Ji
Department of Medicine, Keck School of Medicine of USC, University of Southern California

Organelle stress and Liver injuries often occur in HIV infected patients who are under anti-HIV therapies, yet few molecular off-targets of anti-HIV drugs have been identified in the liver. We found through total RNA sequencing that the transcription of a host protease RCE1 was affected in HepG2 cells treated with anti-HIV protease inhibitors, ritonavir and lopinavir. Levels of RCE1 protein were inhibited in HepG2 and primary mouse hepatocytes and in the liver of mice treated with the anti-HIV drugs, which were accompanied with inhibition of two potential substrates of RCE1, small GTP binding protein Rab13 and Rab18 that are with a common CAAX motif and known to regulate the ER-Golgi traffic or lipogenesis. Neither Rce1 transcription nor RCE1 protein level was inhibited by the organelle stress-inducing agent, Brefeldin A that is known to interfere with the ER-Golgi traffic causing Golgi stress. Knocking down Rce1 with RNA interference increased ritonavir and lopinavir-induced cell death as well as expression of Golgi stress response markers, TFE3, HSP47 and GCP60 in both primary mouse hepatocytes and mouse liver, and deteriorated alcohol-induced ALT and fatty liver injury in mice. In addition, overexpressing Rab13 or Rab18 in primary human hepatocytes reduced partially the anti-HIV drugs and alcohol-induced Golgi fragmentation, Golgi stress response and cell death injury. Thus, we identified a novel mechanism linking a hepatic protease and its substrates, small GTP binding proteins, to the anti-HIV protease inhibitors-induced Golgi dysfunction, organelle stress response and fatty liver injury (supported by NIDA/NIH grant No. DA042632).